PH-284

PH-284 is an investigational small molecule drug belonging to a novel class called vomeropherins. These compounds are self-administered intranasally, where they bind to peripheral chemosensory receptors in the nasal passages. This interaction generates neural impulses that are transmitted via specific pathways to the hypothalamic center, rapidly affecting brain function. PH-284 is being developed for the treatment of anorexia nervosa and for managing loss of appetite and cachexia in patients with cancer or AIDS. It is also considered for other conditions associated with harmful weight loss, such as eating disorders, advanced cancer, AIDS, aging-related appetite loss, acute illness, or pregnancy[1][2][4]. The drug's mechanism involves modulation of chemoreceptor cells and possibly neurotransmitter receptor pathways[7].

Other names

vomeropherin PH-284